ArticleDiscover oncology2025
The role of metabolites in the causal effect of immune cell phenotypes on immunotherapy toxicity risk.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Integrative single-cell analysis revealsFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) therapy have significantly improved survival in cancer patients. However, immune-related adverse events (irAEs) have emerged as a major challenge limiting its therapeutic efficacy. Recent studies have demonstrated that certain immune cell phenotypes and metabolites may be associated with the risk of irAEs. Nevertheless, the precise biological mechanisms for this association remain poorly understood.
methodsUsing genetic variants from large-scale genome-wide association studies (GWAS), we employed two-sample mendelian randomization (MR) to systematically investigate causal relationships among 731 immune cell phenotypes, 1400 metabolites, and the risk of both all-grade and high-grade irAEs. A two-step MR method was employed to further analyze the mediating effects of key immune cell phenotypes and metabolites in irAEs. The inverse-variance weighted (IVW) method served as the primary approach to assess causal relationships, while Cochran's Q test, MR-Egger intercept test, MR-PRESSO, and leave-one-out analysis were employed to evaluate heterogeneity and horizontal pleiotropy.
resultsOur results found that metabolites mediate several causal pathways linking immune cell phenotypes to high-grade irAEs. Specifically, etiocholanolone glucuronide levels partially mediated the causal effect of CCR2 on monocyte in high-grade irAEs, with a mediation proportion of 0.0730 (95% CI 0.0032, 0.1428; P = 0.0403). Thymol sulfate levels partially mediated the causal effect of CD39 on monocyte in high-grade irAEs, with a mediation effect estimate of - 0.0321 (95% CI - 0.0621, - 0.0021; P = 0.0358). Our analysis identified putative associations for all-grade and high-grade irAEs with 10 and 11 immune cell phenotypes and causal relationships with 30 and 36 metabolites, respectively. Sensitivity analysis confirmed the robustness of these associations.
conclusionThis study suggests causal relationships between immune cell phenotypes, metabolites and irAEs. Two metabolites that may act as potential mediating factors between immune cells and high-grade irAEs were identified. Of course, further investigation is warranted to validate these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.